Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
Abstract
The objective of this study was to determine the factors including neuropsychological test performances and cerebrospinal fluid (CSF) biomarkers which can predict disease progression of early Alzheimer's disease (AD) in a Japanese population.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1016/j.trci.2019.06.004
Entities
People
- Atsushi Iwata
- Japanese Alzheimer's Disease Neuroimaging Initiative
- Junichi Ito
- Kazushi Suzuki
- Ken Aoshima
- Michio Kanekiyo
- Ryoko Ihara
- Takeshi Iwatsubo
- Takuya Yagi
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eisai
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- University of Tokyo